human cd4 cell negative selection rosettesep procedure 15022 (STEMCELL Technologies Inc)
90
Structured Review
STEMCELL Technologies Inc
human cd4 cell negative selection rosettesep procedure 15022
Human Cd4 Cell Negative Selection Rosettesep Procedure 15022, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd4+cell+negative+selection+rosettesep+procedure+15022/human+cd4+cell+negative+selection+rosettesep+procedure+15022/pm38043051-101-20-28
Average 90 stars, based on 1 article reviews
Human Cd4 Cell Negative Selection Rosettesep Procedure 15022, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd4+cell+negative+selection+rosettesep+procedure+15022/human+cd4+cell+negative+selection+rosettesep+procedure+15022/pm38043051-101-20-28
Average 90 stars, based on 1 article reviews
human cd4 cell negative selection rosettesep procedure 15022 - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Fluorescence:Article Title: Human CD4+CD25+ T cells expressing a chimeric antigen receptor against aberrant superoxide dismutase 1 trigger antigen-specific immunomodulation. Article Snippet: Background aims: Amyotrophic lateral sclerosis (ALS) is a fatal disease associated with motor neuron degeneration, accumulation of aggregated misfolded proteins and neuroinflammation in motor regions of the central nervous system (CNS).. Clinical trials using regulatory T cells (Tregs) are ongoing because of Tregs’ immunomodulatory function, ability to traffic to the CNS, high numbers correlating with slower disease in ALS and disease-modifying activity in ALS mouse models.. In the current study, a chimeric antigen receptor (CAR) was developed and characterized in human Tregs to enhance their immunomodulatory activity when in contact with an ALS protein aggregate. Isolation:Article Title: Human CD4+CD25+ T cells expressing a chimeric antigen receptor against aberrant superoxide dismutase 1 trigger antigen-specific immunomodulation. Article Snippet: Background aims: Amyotrophic lateral sclerosis (ALS) is a fatal disease associated with motor neuron degeneration, accumulation of aggregated misfolded proteins and neuroinflammation in motor regions of the central nervous system (CNS).. Clinical trials using regulatory T cells (Tregs) are ongoing because of Tregs’ immunomodulatory function, ability to traffic to the CNS, high numbers correlating with slower disease in ALS and disease-modifying activity in ALS mouse models.. In the current study, a chimeric antigen receptor (CAR) was developed and characterized in human Tregs to enhance their immunomodulatory activity when in contact with an ALS protein aggregate. Purification:Article Title: Human CD4+CD25+ T cells expressing a chimeric antigen receptor against aberrant superoxide dismutase 1 trigger antigen-specific immunomodulation. Article Snippet: Background aims: Amyotrophic lateral sclerosis (ALS) is a fatal disease associated with motor neuron degeneration, accumulation of aggregated misfolded proteins and neuroinflammation in motor regions of the central nervous system (CNS).. Clinical trials using regulatory T cells (Tregs) are ongoing because of Tregs’ immunomodulatory function, ability to traffic to the CNS, high numbers correlating with slower disease in ALS and disease-modifying activity in ALS mouse models.. In the current study, a chimeric antigen receptor (CAR) was developed and characterized in human Tregs to enhance their immunomodulatory activity when in contact with an ALS protein aggregate. Selection:Article Title: Human CD4+CD25+ T cells expressing a chimeric antigen receptor against aberrant superoxide dismutase 1 trigger antigen-specific immunomodulation. Article Snippet: Background aims: Amyotrophic lateral sclerosis (ALS) is a fatal disease associated with motor neuron degeneration, accumulation of aggregated misfolded proteins and neuroinflammation in motor regions of the central nervous system (CNS).. Clinical trials using regulatory T cells (Tregs) are ongoing because of Tregs’ immunomodulatory function, ability to traffic to the CNS, high numbers correlating with slower disease in ALS and disease-modifying activity in ALS mouse models.. In the current study, a chimeric antigen receptor (CAR) was developed and characterized in human Tregs to enhance their immunomodulatory activity when in contact with an ALS protein aggregate. |